Triple

T24850894

Position	Surface form	Disambiguated ID	Type / Status
Subject	RNA therapeutics	`E621880`	entity
Predicate	regulatoryApprovedExample	`P24602`	FINISHED
Object	inclisiran Inclisiran is a small interfering RNA (siRNA) cholesterol-lowering drug that targets PCSK9 to reduce LDL cholesterol and cardiovascular risk.	`E1654313`	NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini

Instruction

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Input

Phrase: inclisiran | Statement: [RNA therapeutics, regulatoryApprovedExample, inclisiran]

NEDg Description generation gpt-5.1

Instruction

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Input

Entity: inclisiran
Triple: [RNA therapeutics, regulatoryApprovedExample, inclisiran]

Generated description

Inclisiran is a small interfering RNA (siRNA) cholesterol-lowering drug that targets PCSK9 to reduce LDL cholesterol and cardiovascular risk.

PD Predicate disambiguation gpt-5-mini-2025-08-07

Target predicate: regulatoryApprovedExample
Context triple: [RNA therapeutics, regulatoryApprovedExample, inclisiran]

A. hasRegulatoryApproval chosen
Indicates that an entity has received formal authorization or clearance from a relevant regulatory authority to operate, be sold, or be used in a specified context.
B. regulationStatus
Indicates the regulatory condition or compliance state that applies to an entity under relevant rules or laws.
C. hasRegulatedBy
Indicates that one entity is subject to control, governance, or rules imposed by another entity.
D. regulatoryOutcome
Indicates the result or consequence of a regulatory process, such as approval, rejection, modification, or other formal decision made by a regulatory authority regarding an entity or action.
E. appliesRegulatoryStandard
Indicates that one entity enforces or uses a specific regulatory standard in relation to another entity or context.
F. None of above.

Provenance (6 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step	Stage	Batch ID	Status	When
creating	Elicitation	`batch_69e2fac297e481909d3aedc75f585e42`	completed	April 18, 2026, 3:30 a.m.
NER	Named-entity recognition	`batch_69f60c3b09488190ade1b69ff7f0df0e`	completed	May 2, 2026, 2:37 p.m.
NED1	Entity disambiguation (via context triple)	`batch_6a101c533540819094411da3f6178d1d`	completed	May 22, 2026, 9:05 a.m.
NEDg	Description generation	`batch_6a102814f838819094ed41d653039f72`	completed	May 22, 2026, 9:55 a.m.
NED2	Entity disambiguation (via description)	`batch_6a10294485508190a91d9ec391181047`	completed	May 22, 2026, 10 a.m.
PD	Predicate disambiguation	`batch_69f60b8461ac81908c5bd3d73eed59f4`	completed	May 2, 2026, 2:34 p.m.

Created at: April 18, 2026, 5:20 a.m.